Maxim analyst Jason McCarthy downgraded Blue Water Biotech to Hold from Buy as the firm awaits clarity on the company’s commercial programs and vaccine pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BWV:
- Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q
- Blue Water Vaccines, Inc. (BWV) Q2 Earnings Cheat Sheet
- Blue Water, Copay Consultants collaborate to build copay assistance programs
- Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds
- Blue Water Biotech announces exercise of warrants